newsfilter
← Latest News
Business Wire·

U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer

Bayer’s supplemental New Drug Application (sNDA) is based on results from the Phase III OASIS-4 investigational study for the treatment of moderate to severe vasomotor symptoms in women receiving endocrine therapy for